Clinical trials: TACE
Confirmed Diagnosis of Hepatocellular Carcinoma, Patients Who Are Scheduled to Undergo Transarterial Chemobolization, Systemic Therapy Surgery
Fibroscan Study in HCC
In patients with HCC undergoing therapy 1. We aim to determine the prognostic significance of liver stiffness in patients with HCC 2.
- Conditions
- Confirmed Diagnosis of Hepatocellular Carcinoma, Patients Who Are Scheduled to Undergo Transarterial Chemobolization, Systemic Therapy Surgery, Child's A to C Cirrhosis
- Trial name
- NCT01796145
- Testing
- Fibroscan
- Where
- Hong Kong
- Volunteers
- 207 people
- Sponsor
- Chinese University of Hong Kong
Unresectable Hepatocellular Carcinoma
Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma
Primary liver cancer is the second most common cause of cancer death in China, and hepatocellular carcinoma (HCC) represents more than 80% of liver cancer cases.
- Trial name
- NCT04947956
- Testing
- Camrelizumab
- Volunteers
- 1,000 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication
Although it is commonly accepted that antiviral therapy should be commenced before or during hepatocellular carcinoma (HCC) treatment if the patients have high viral loads and elevated ALT or total bilirubin values with signs of…
- Trial name
- NCT01894269
- Testing
- Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Tumor Response Rate, Overall Survival
TILA-TACE in Treatment of Hepatocellular Carcinoma
To validate the tumor response rate: in the previous study, the investigators showed that TILA-TACE achieved 100% tumor response rate.
- Trial name
- NCT03910140
- Testing
- TILA-TACE treatment
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma Stage III
Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma
The purpose of present study is to evaluate whether per-operative neoadjuvant therapy combined with surgery could improve the 1-year disease-free survival of stage III hepatocellular carcinoma patients.
- Trial name
- NCT04961138
- Testing
- Transhepatic Arterial Chemotherapy And Embolization (TACE), Surgery
- Volunteers
- 164 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Carcinoma, Hepatocellular
DCE-MRI for Assessment of Response to TACE of HCC
This study is conducted to evaluate dynamic contrast-enhanced MRI to quantify the efficacy of trans-arterial chemoembolization by comparing imaging results before and after treatment for at least one hepatic tumor and to look at…
- Trial name
- DCE-MRI (NCT02878109)
- Testing
- Post-treatment phase group, Pre-treatment phase group
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Hepatocellular Carcinoma
TACE Combined With Methylcantharidimide Tablets in the Treatment of Large and Unresectable Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with methylcantharidimide tablets in the treatment of patients with large and unresectable hepatocellular…
- Trial name
- NCT03996681
- Testing
- methylcantharidimide tablets
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Suzhou Municipal Hospital
Child-Pugh Class A, Child-Pugh Class B
Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
This pilot clinical trial studies stereotactic body radiation therapy (SBRT) and transarterial chemoembolization (TACE) in treating patients with liver cancer that cannot be removed by surgery.
- Conditions
- Child-Pugh Class A, Child-Pugh Class B, Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma
- Trial name
- NCT02507765
- Testing
- Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy, Transarterial Chemoembolization
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Carcinoma, Hepatocellular, Hepatobiliary Neoplasm
Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma
To determine the efficacy and toxicity of TACE combined with SBRT
- Conditions
- Carcinoma, Hepatocellular, Hepatobiliary Neoplasm, Liver Carcinoma
- Trial name
- NCT01020812
- Testing
- TACE, SBRT
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Hepatocellular Carcinoma
PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7
This is a retrospective study that retrospectively included patients with intermediate and advanced HCC beyond up to seven who received first-line treatment with PD-1/PD-L1 inhibitors and anti-angiogenic agents combined…
- Trial name
- NCT06423144
- Testing
- TACE/HAIC, PD-1/PD-L1 inhibits and anti-angiogenic agents
- Volunteers
- 150 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma (HCC), Living Donor Liver Transplantation
Efficacy of Loco-regional Treatment for Hepatocellular Carcinoma Prior to Living Donor Liver Transplantation in Egypt
This study aimed to analyze the outcomes of loco-regional treatment prior Living Donor Liver Transplantation in patients with HCC.
- Trial name
- NCT02990351
- Testing
- loco regional therapies for HCC
- Volunteers
- 29 people
- Sponsor
- Ain Shams University
Hepatocellular Carcinoma
Cytoreductive Surgery and Transarterial Chemoembolization (TACE) Versus TACE for Hepatocellular Carcinoma
The aim of this study is to compare the surgical outcomes of cytoreductive surgery followed by Transarterial Chemoembolization (TACE) with TACE alone in patients with MNHCC so as to establish a treatment standard for MNHCC.
- Trial name
- TACE (NCT00820157)
- Testing
- Cytoreductive Surgery, TACE
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Stage IV Melanoma Patients With Unresectable Liver Metastases
TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma Patients
The Aim is to evaluate safety and efficacy of TACE with doxorubicin-loaded DC beads in melanoma patients with liver metastasis. This is a pilot study with the aim of recruiting 20 patients, this is a feasibility study.
- Trial name
- NCT01409733
- Testing
- TACE using Drug Eluting Beads loaded with Doxorubicin
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Heidelberg University
Gastric Cancer With Liver Metastases
TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study.
This study is a multicenter, single-arm prospective clinical trial designed to evaluate the efficacy of TACE combined with thermal ablation, antibody-drug conjugates, immune checkpoint inhibitors, and first-line chemotherapy for…
- Trial name
- NCT07602140
- Testing
- TACE combined with thermal ablation, Targeted Therapy, Immunotherapy
- Volunteers
- 40 people
- Sponsor
- Shandong Provincial Hospital
Carcinoma, Hepatocellular
TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients
This study was designed to evaluate the effectiveness of Anlotinib in middle-advanced Hepatocellular Carcinoma (HCC) Patients.
- Trial name
- NCT04066543
- Testing
- TACE, Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Carcinoma, Hepatocellular
Effect of Tumor Micronecrosis on Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepatocellular Carcinomas
Micronecrosis is a novel pathological feature of hepatocellular carcinoma (HCC). This study was aimed at evaluating the effect of tumor micronecrosis on postoperative transcatheter arterial chemoembolization (TACE) in patients…
- Trial name
- NCT05352204
- Testing
- transcatheter arterial chemoembolization
- Where
- 2 sites in China
- Volunteers
- 900 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma
Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC)
this multi-center prospective cohort study is to evaluate the efficacy and the safety of drug-eluting bead TACE compared with conventional TACE in terms of objective response in unresectable HCC
- Trial name
- NCT03969576
- Testing
- DEB-TACE, cTACE
- Where
- China
- Volunteers
- 344 people
- Sponsor
- Air Force Military Medical University, China
Carcinoma, Hepatocellular
A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma
The objective of this Phase II trial is to compare the efficacy and safety of 6 months of treatment with thymalfasin plus trans arterial chemoembolization (TACE) with TACE alone in adult patients with non-surgical hepatocellular…
- Trial name
- NCT00082082
- Testing
- Thymalfasin (thymosin alpha-1), Trans arterial chemoembolization (TACE)
- Where
- 5 sites in United States
- Sponsor
- SciClone Pharmaceuticals
Hepatocellular Carcinoma
Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma
Safety and efficacy of doxorubicin-eluting-bead embolization in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT02525380
- Testing
- Device(DC Bead)
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Seoul National University Hospital
Precision Cell Immunotherapy, Transcatheter Arterial Chemoembolization
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
To evaluate the safety and effectiveness of cell therapy using precision cells Combined With TACE in Advanced Liver Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of…
- Conditions
- Precision Cell Immunotherapy, Transcatheter Arterial Chemoembolization, Advanced Liver Cancer
- Trial name
- NCT02873442
- Testing
- TACE, Precision Cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ningbo Cancer Hospital